MIGRENA - PI-House – Centrum Badań Klinicznych

Clinical trials

It is important to remember that every drug available in pharmacies has been evaluated in clinical trials.

MIGRAINE

Clinical trials ^{source: clinicaltrials.gov}
Study 1

Other Clinical Trials

Check what tests we are currently conducting in our facility.

More

Contact form

if you are interested participation in a clinical trial - submit your form to recruiting department

Name

E-mail

Phone

Miasto

Message

Agreement
By sending the contact form, you agree to be contacted by Centrum Badań Klinicznych PI-House sp. Z oo with its registered office in Gdańsk, by e-mail in matters related to clinical trials. Additionally, you may indicate a telephone number that we will be able to use in the same case - if this form of contact is more convenient for you. You have the right to request the data controller to access your data, rectify it, delete or limit processing, or object to processing, as well as the right to lodge a complaint with the supervisory authority. More information at: https://pihouse.pl/ochrona_danych/

General information

Centrum Badań Klinicznych PI-House sp. z o. o.
NIP: 9571059089 | EU VAT ID: PL9571059089
REGON: 221506777 | KRS: 0000394618
Share capital: PLN 60,000
Entry number in the Register of
Health Care Providers: 000000154510

Data Protection – find out more..

Contact

ul. Na Zaspę 3,
80-546 Gdańsk

+48 58 719 22 22

FAX: +48 58 719 22 21

pihouse@pihouse.pl

CBK PI-HOUSE

START

Info SARS-COV-2

About PI-House

CLINIC

Contact

Menu

English (UK)

Polski English (UK)

Personal Data Protection Personal data protection

We have a personal data protection policy in accordance with the GDPR. This site uses cookies to provide services at the highest level. By continuing to use the site, you agree to their use.

Personal Data Administrator is Centrum Badań Klinicznych PI-House Sp. z o. o with its registered office in Gdańsk (80-546), ul. Na Zaspa 3, registered in the Gdańsk-Północ District Court in Gdańsk, VII Commercial Department of the National Court Register under the number KRS: 0000394618, NIP: 9571059089.

Please be advised that the Data Administrator has appointed a Personal Data Protection Inspector. You have the right to contact the Data Protection Officer directly using the email address: iod@pihouse.pl.

Learn more by clicking this link

We run a policy of personal data protection according to ROPE.
Our website uses cookies to improve your experience. By continuing to browse our website, you are agreeing to our use of cookies.
The administrator of Personal Data is the Centrum Badań Klinicznych PI-House Sp. z o. o. with headquarters in Gdańsk (80-546), ul. Na Zaspa 3, registered at the District Court Gdańsk - Północ in Gdańsk, VII Commercial Division of the National Court Register under KRS number: 0000394618, Taxpayer identification number: 9571059089.
Please be advised that the Data Administrator has appointed the Data Protection Inspector. You have the right to contact the Data Protection Supervisor using the e-mail address: iod@pihouse.pl.
Learn more by clicking this link

Study 1

Return

Study title: Open-label long-term safety study of esketamine nasal spray dose extension in treatment-resistant depression
Therapeutic area: Treatment-resistant depressive disorder
Phase: III
Start Date: June 9, 2016
End date: December 31, 2022
Status: Not recruiting
Sponsor Name: Janssen Research & Development, LLC

Study 1

RETURN

Study title: Open-label long-term safety study of esketamine nasal spray dose extension in treatment-resistant depression
Therapeutic area: Treatment-resistant depressive disorder
Phase: III
Start Date: June 9, 2016
End date: December 31, 2022
Status: Not recruiting
Sponsor Name: Janssen Research & Development, LLC

Study 1

RETURN

Study title: Long-term, multicentre, randomized, double-blind, controlled, parallel group study of the safety and efficacy of Lemborekxant in people with insomnia disorders
Therapeutic area: Disorder of insomnia
Phase: III
Start Date: November 15, 2016
End date: January 8, 2019
Status: Not recruiting
Sponsor Name: Eisai Inc.

Study 1

RETURN

Study title: Adaptive, multicentre, prospective, randomized, double-blind, placebo-controlled phase IIb / III study of the safety and efficacy of NaBen® (DAAO inhibitor) as an additional treatment for schizophrenia in adults
Therapeutic area: schizophrenia
Phase: IIb / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx

Study 2

RETURN

Study title: Adaptive Phase II / III study, two-part, double-blind, randomized, placebo-controlled, dose-titled multicenter study of the safety and efficacy of NaBen® as add-on therapy with clozapine for the treatment of symptoms of refractory schizophrenia in adults
Therapeutic area: schizophrenia
Phase: II / III
Start Date: March 29, 2017
End date: December 31, 2021
Status: Recruiting
Sponsor Name: SyneuRx

Personal Data Protection Personal data protection

We have a personal data protection policy in accordance with the GDPR. This site uses cookies to provide services at the highest level. By continuing to use the site, you agree to their use.
Personal Data Administrator is Centrum Badań Klinicznych PI-House Sp. z o. o with its registered office in Gdańsk (80-546), ul. Na Zaspa 3, registered in the Gdańsk-Północ District Court in Gdańsk, VII Commercial Department of the National Court Register under the number KRS: 0000394618, NIP: 9571059089.
Please be advised that the Data Administrator has appointed a Personal Data Protection Inspector. You have the right to contact the Data Protection Officer directly using the email address: iod@pihouse.pl.
Learn more by clicking this link
We run a policy of personal data protection according to ROPE.
Our website uses cookies to improve your experience. By continuing to browse our website, you are agreeing to our use of cookies.
The administrator of Personal Data is the Centrum Badań Klinicznych PI-House Sp. z o. o. with headquarters in Gdańsk (80-546), ul. Na Zaspa 3, registered at the District Court Gdańsk - Północ in Gdańsk, VII Commercial Division of the National Court Register under KRS number: 0000394618, Taxpayer identification number: 9571059089.
Please be advised that the Data Administrator has appointed the Data Protection Inspector. You have the right to contact the Data Protection Supervisor using the e-mail address: iod@pihouse.pl.
Learn more by clicking this link